Rapid advances in cell therapy have resulted in complex processes. As they move toward the clinic, manufacturers are attempting to scale up or scale out the processes using legacy equipment that often was designed for other purposes.
For manufacturers, this means transport cell cultures from instrument to instrument. Much of the work is still manual, which delays optimal timelines and comes with risks or contamination, cell stress, and cell loss. For payers and patients, this means high price tags that put these specialized therapies out of reach.
The end-to-end automation that could address those needs of manufacturers, payers, and patients is still lacking in the commercial cell therapy processing sector. But, within the next few years, that can change.
